% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Krber:282683,
      author       = {S. Körber$^*$ and M. Röhrich and L. Walkenbach and J.
                      Liermann and P. L. Choyke and C. Fink and C. Schroeter and
                      A.-M. Spektor and K. Herfarth$^*$ and T. Walle$^*$ and J.
                      Calais and H.-U. Kauczor and D. Jaeger and J. Debus$^*$ and
                      U. Haberkorn$^*$ and F. L. Giesel},
      title        = {{I}mpact of 68{G}a-{FAPI} {PET}/{CT} on {S}taging and
                      {O}ncologic {M}anagement in a {C}ohort of 226 {P}atients
                      with {V}arious {C}ancers.},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {11},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-01829},
      pages        = {1712-1720},
      year         = {2023},
      note         = {#EA:E050# / 2023 Nov;64(11):1712-1720},
      abstract     = {Since the development of fibroblast activation
                      protein-targeted radiopharmaceuticals, 68Ga-fibroblast
                      activation protein inhibitor (FAPI) PET/CT has been found to
                      be suitable for detecting primary and metastatic lesions in
                      many types of tumors. However, there is currently a lack of
                      reliable data regarding the clinical impact of this family
                      of probes. To address this gap, the present study aimed to
                      analyze the clinical impact of 68Ga-FAPI PET/CT by examining
                      a large cohort of patients with various tumors. Methods: In
                      total, 226 patients (137 male and 89 female) were included
                      in this retrospective analysis. Pancreatic cancer and head
                      and neck cancers were the most common tumor types in this
                      cohort. TNM stage and oncologic management were initially
                      determined with gold standard imaging, and these results
                      were compared with 68Ga-FAPI PET/CT. Changes were classified
                      as major and minor. Results: For $42\%$ of all patients, TNM
                      stage was changed by 68Ga-FAPI PET/CT results. Most of these
                      changes resulted in upstaging. A change in clinical
                      management occurred in 117 of 226 patients. Although a major
                      change in management occurred in only $12\%$ of patients,
                      there was a significant improvement in the ability to
                      accurately plan radiation therapy. In general, the highest
                      clinical impact of 68Ga-FAPI PET/CT imaging was found in
                      patients with lung cancer, pancreatic cancer, and head and
                      neck tumors. Conclusion: 68Ga-FAPI PET/CT is a promising
                      imaging probe that has a significant impact on TNM stage and
                      clinical management. 68Ga-FAPI PET/CT promises to be a
                      crucial new technology that will improve on conventional
                      radiologic imaging methods such as contrast-enhanced CT and
                      contrast-enhanced MRI typically acquired for cancer
                      staging.},
      keywords     = {FAPI (Other) / PET/CT (Other) / management (Other) /
                      radiation therapy (Other) / staging (Other)},
      cin          = {E050 / F230 / HD01 / E060},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)F230-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)E060-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37678928},
      doi          = {10.2967/jnumed.123.266046},
      url          = {https://inrepo02.dkfz.de/record/282683},
}